ITUS CORPORATION (NASDAQ:ITUS) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07 Submission of Matters to a Vote of Security Holders.
The Annual Meeting of Stockholders (the “Annual Meeting”) of ITUS Corporation (the “Company”) was held on Friday, September 22, 2017 at the DoubleTree Hotel, 2050 Gateway Place, San Jose, CA 95110. Stockholders of record at the close of business on July 28, 2017 were entitled to one vote for each share of common stock held. On July 28, 2017, there were 15,120,293 shares of common stock issued and outstanding. At the Annual Meeting, the stockholders of the Company voted on the following proposals:
1. To elect five directors nominated by the Board of Directors (the “Board”) to serve for a one-year term that expires at the 2018 Annual Meeting of Stockholders, and until their successors are elected and qualified. Each nominee for director was elected by a vote of the stockholders as follows:
|
For |
Withheld |
Broker Non-Votes |
|
|
Dr. Amit Kumar |
2,434,442 |
97,051 |
7,836,552 |
|
Bruce Johnson |
2,430,197 |
101,276 |
7,836,552 |
|
Dr. John Monahan |
2,428,795 |
102,678 |
7,836,552 |
|
Lewis H. Titterton, Jr. |
2,436,996 |
94,477 |
7,836,552 |
|
Richard H. Williams |
2,430,211 |
101,262 |
7,836,552 |
2. To ratify the appointment of Haskell & White LLP, an independent registered public accounting firm, as the Company’s independent auditors for fiscal year 2017. The proposal was approved by a vote of stockholders as follows:
|
For |
Against |
Abstain |
|
10,282,600 |
8,192 |
77,233 |
About ITUS CORPORATION (NASDAQ:ITUS)
ITUS Corporation is engaged in developing a diagnostic platform called Cchek, for the early detection of tumor-based cancers. The Cchek cancer detection platform measures a patient’s immune response to a malignancy by detecting the presence, absence and quantity of certain immune cells that exist in and around a tumor and that enter the blood stream. Instead of seeking to alter or boost the body’s immune system and its ability to destroy cancer cells, the Company has developed techniques and protocols for measuring the subtle immunological changes that occur in the blood stream during tumor development. Through its protocols, the Company has detected the biomarkers in the peripheral blood of biopsy verified cancer patients, and in distinguishing the blood of healthy patients from the blood of cancer patients.
